Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Natera (NTRA) through the VizualStocks API.
Natera revenue associated with payers located in the Americas outside the United States. The geography follows the payer that reimburses or purchases the test, not necessarily the patient's residence or the laboratory where the sample was processed.
americasExcludingUnitedStatesRevenueNatera revenue associated with payers located in Asia-Pacific and other markets not included in its named U.S., other-Americas or EMEIA regions. The geography follows the payer that reimburses or purchases the test, not necessarily the patient's residence or the processing laboratory.
asiaPacificAndOtherRevenueNatera revenue associated with payers located in Europe, the Middle East, India and Africa. The geography follows the payer that reimburses or purchases the test, not necessarily the patient's residence or the laboratory where the sample was processed.
europeMiddleEastIndiaAndAfricaRevenueRevenue Natera expects to collect from commercial insurers, Medicare, Medicaid and other third-party payers for genetic tests delivered to patients. The amount is recognized when results are delivered and estimated using coverage terms, reimbursement history, denials, co-pays and deductibles, so later collection updates can create revenue true-ups.
insuranceCarriersRevenueRevenue from domestic and international laboratory partners that distribute Natera tests and generally bill clinics, patients or insurers themselves. Natera earns a fixed price per test or a share of the partner's collections and recognizes revenue when the test result is delivered.
laboratoryPartnersRevenueRevenue Natera expects to collect directly from patients for genetic testing, including self-pay amounts and insurance co-pays and deductibles. It is recognized when test results are delivered and reflects estimated collectability rather than the full amount initially billed.
patientsRevenueNumber of test samples Natera received in its own laboratories, entered into its systems and routed into the appropriate testing workflow during the period. It is a subset of Tests Processed because it excludes units run by outside laboratories through Natera's Constellation platform.
testsAccessionedTotal Natera test volume handled during the period, equal to tests accessioned in Natera's laboratories plus units processed by outside laboratories using its licensed Constellation workflow. It measures operating volume before every test has necessarily produced a reportable result or recognized revenue.
testsProcessedNumber of Natera tests for which a result was delivered to the ordering customer during the period, including tests run inside and outside Natera's laboratories. Reported units are the volume basis for test revenue, so this count can trail Tests Processed because samples have not all completed the workflow.
testsReportedNumber of completed test results delivered during the period from samples run in Natera's own laboratories. It excludes units reported by outside laboratories through Constellation and is therefore a subset of total Tests Reported.
testsReportedInLaboratoryNatera revenue associated with payers located in the United States across its oncology, women's-health and organ-health testing. The geography follows the payer that reimburses or purchases the test, and U.S. payers account for roughly 98% of company revenue.
unitedStatesRevenue